Neurocrine Biosciences (NBIX) Getting Somewhat Positive Media Coverage, Report Finds
Media headlines about Neurocrine Biosciences (NASDAQ:NBIX) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.4120929465146 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several analysts recently weighed in on NBIX shares. Robert W. Baird reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $76.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Deutsche Bank reaffirmed a “buy” rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Jefferies Group reaffirmed a “buy” rating and issued a $69.00 price objective (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $84.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 5th. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $78.88.
Shares of Neurocrine Biosciences (NASDAQ NBIX) traded up $0.08 during mid-day trading on Monday, hitting $70.57. The stock had a trading volume of 605,029 shares, compared to its average volume of 1,098,725. Neurocrine Biosciences has a 12-month low of $37.35 and a 12-month high of $75.98. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.
In other news, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the completion of the transaction, the insider now directly owns 84,596 shares in the company, valued at $6,010,545.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary A. Lyons sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $72.92, for a total value of $729,200.00. Following the transaction, the director now owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The disclosure for this sale can be found here. Insiders have sold 90,877 shares of company stock valued at $6,568,617 over the last 90 days. 4.80% of the stock is owned by corporate insiders.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.